Cancer Family

Urinary System Neoplasm

Non-malignant965 active trials28 approved drugs109 evidence items

NCIt: C3431

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Literature

Linked publications (268)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 151–175 of 268 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Urine and Blood-Derived MicroRNAs in Patients with Kidney Cancer: A Review of Clinical Utility and Recent Developments.
Samuel Y R Chen, Serina Quach, Vladislav Nikitin et al. · Cells · Aug 18, 2026 · PMID 42645213 · candidate dictionary pubmed
Disease-free survival as a surrogate outcome for localized kidney cancer-A systematic review and meta-analysis.
Constanza Martinez, David Chen, Russell Leong et al. · Cancer · Aug 15, 2026 · PMID 42590929 · candidate dictionary pubmed
Re: Siva S, Ali M, Hardcastle N, et al. Ultra-hypofractionated Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: 5-Year Outcomes from a Pooled Analysis of the FASTRACK Trials. Lancet Oncol. In press. https://doi.org/10.1016/S1470-2045(26)00170-1 and re: Siva S, Pryor D, Martin J, et al. Long-term Outcomes of Stereotactic Ablative Body Radiotherapy for Primary Kidney Cancer (TROG 15.03 FASTRACK II): A Multicentre, Non-randomised, Phase 2 Study. Lancet Oncol. In press. https://doi.org/10.1016/S1470-2045(26)00091-4.
Umberto Capitanio, Axel Bex, Grant D Stewart et al. · Eur Urol · Aug 14, 2026 · PMID 42601237 · candidate dictionary pubmed
Treatment Patterns and Long-Term Survival Outcomes in Muscle-Invasive Bladder Cancer: A Decade-Long Single-Institution Retrospective Cohort Study.
Fajar Rafi Ranjha, Asma Rashid, Abdullah Adnan et al. · J Cancer Allied Spec · Mar 1, 2026 · PMID 42725309 · candidate dictionary pubmed
Biomarker-guided selection of intravesical therapy in high-risk non-muscle invasive bladder cancer: A contemporary review.
Willian Ito, Isamu Tachibana · Ther Adv Urol · Jan 1, 2026 · PMID 42694519 · candidate dictionary pubmed
Differential effects of BCG-Russia and BCG-TICE on trained immunity: Potential implications for bladder cancer immunotherapy.

Richard W Nauman, Peter A Greer, Andrew W Craig et al. · PLoS One · Jan 1, 2026 · PMID 42726801 · candidate dictionary pubmed

Guideline-recommended post-operative intravesical chemotherapy and cystoscopic surveillance among patients with low- and intermediate-risk non-muscle invasive bladder cancer.

Michael J Shulman, Valerie S Lee, Janise M Roh et al. · Bladder Cancer · Jan 1, 2026 · PMID 42732153 · candidate dictionary pubmed

The burden of bladder cancer and kidney cancer attributable to smoking in Latin America and the Caribbean from 1990 to 2023 and projections to 2050.

Jia Deng, Bing Yang, Zhenzhen Wu et al. · Tob Induc Dis · Jan 1, 2026 · PMID 42746221 · candidate dictionary pubmed

A recurrent cancer-associated fibroblast/TGF-beta/endothelial barrier direction is associated with immune exclusion and checkpoint resistance in bladder cancer: a public multi-cohort transcriptomic study.

Yuye Wu, Guangjie Li, Lixing Jiang et al. · PLoS One · Jan 1, 2026 · PMID 42771603 · candidate dictionary pubmed

PAK4-targeting PROTAC inhibits bladder cancer cell proliferation.

Shan Xu, Hongjun Xie, Zhao Yang et al. · PLoS One · Jan 1, 2026 · PMID 42766568 · candidate dictionary pubmed

Targeted Nanoparticles for PROTAC-Mediated JAK1/JAK2 Degradation for Bladder Cancer Treatment.

Weihong Ding, Xinyue Zhang, Hongdan Wu et al. · Int J Nanomedicine · Jan 1, 2026 · PMID 42802799 · candidate dictionary pubmed

A candidate PPARγ to GPX4 axis in ferroptosis suppression and platinum resistance in bladder cancer: evidence appraisal and a testable research agenda.

Shenjuan Li, Hongwei Peng, Gang Li et al. · J Cancer · Jan 1, 2026 · PMID 42807712 · candidate dictionary pubmed

Integrated molecular analysis of clear-cell renal cell carcinoma.

· Nat Genet · 2013 · PMID 23797736 · validated cbioportal_study pubmed

Comprehensive molecular characterization of clear cell renal cell carcinoma.

· Nature · 2013 · PMID 23792563 · validated cbioportal_study pubmed

Recurrent internal tandem duplications of BCOR in clear cell sarcoma of the kidney.

· Nat Commun · 2015 · PMID 26573325 · validated civic_curation pubmed

Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma.

· Int J Cancer · 2008 · PMID 18464292 · validated civic_curation pubmed

PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation.

· Br J Cancer · 2013 · PMID 23989949 · validated civic_curation pubmed

ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy.

· J Urol · 2015 · PMID 26162296 · validated civic_curation pubmed

The T393C polymorphism of the G alpha s gene (GNAS1) is a novel prognostic marker in bladder cancer.

· Cancer Epidemiol Biomarkers Prev · 2005 · PMID 15824158 · validated civic_curation pubmed

The GNAS1 T393C polymorphism predicts survival in patients with clear cell renal cell carcinoma.

· Clin Cancer Res · 2006 · PMID 16467086 · validated civic_curation pubmed

Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review.

· Oncotarget · 2017 · PMID 28103578 · validated civic_curation pubmed

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.

· J Clin Oncol · 2016 · PMID 26951309 · validated civic_curation pubmed

Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.

· Eur Urol · 2017 · PMID 27751729 · validated civic_curation pubmed

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

· J Clin Oncol · 2018 · PMID 29320312 · validated civic_curation pubmed

Renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions: clinical experience and literature review.

· Future Oncol · 2015 · PMID 26169997 · validated civic_curation pubmed